Research programme: cyclophilin inhibitors - SCYNEXIS

Drug Profile

Research programme: cyclophilin inhibitors - SCYNEXIS

Alternative Names: Cyclophilin D inhibitors - SCYNEXIS; SCY-575; SCY-641

Latest Information Update: 05 Nov 2014

Price : $50

At a glance

  • Originator SCYNEXIS
  • Class
  • Mechanism of Action Cyclophilin D inhibitors; Cyclophilin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Eye disorders; Hepatitis B; Hepatitis C
  • Research Atopic dermatitis; Chronic heart failure; Inflammation; Muscular dystrophies; Neurodegenerative disorders; Reperfusion injury; Rheumatoid arthritis
  • No development reported HIV infections; Ischaemia; Wounds

Most Recent Events

  • 05 Nov 2014 Preclinical development is ongoing in USA
  • 13 Jun 2013 No development reported - Early research in HIV infections, Ischaemia and Wounds in USA (unspecified route)
  • 13 Jun 2013 Early research in Atopic dermatitis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top